Combination of a cb1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease

Abstract

The present invention relates to the combination of one or more CB1 antagonist azetidine derivatives and of one or more products which activate dopaminergic neurotransmission in the brain, to the pharmaceutical compositions comprising them and to their use in the treatment of Parkinson's disease.

1 . A pharmaceutical composition comprising N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide or a pharmaceutically acceptable salt thereof and a mixture of Labrafil and Labrasol.  
   
   
       2 . The composition according to  claim 1 , wherein said mixture of Labrafil and Labrasol is present in a weight ratio of about 40:60.  
   
   
       3 . The composition according to  claim 1 , which is suitable oral administration.  
   
   
       4 . A method for the preparation of a pharmaceutical composition suitable for oral administration, which comprises mixing N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide with a mixture of Labrafil and Labrasol.  
   
   
       5 . The method according  claim 4 , wherein said mixture of Labrafil and Labrasol is present in a weight ratio of about 40:60.